Loading organizations...
Loading organizations...

Frontier Medicines: Biotech company developing precision medicines for undruggable proteins using chemoproteomics for oncology and immunology.
Frontier Medicines has raised $256.0M across 4 funding rounds.
Key people at Frontier Medicines.
Frontier Medicines has raised $256.0M in total across 4 funding rounds.
Frontier Medicines is a biotechnology company that develops precision medicines targeting previously undruggable disease-causing proteins in oncology and immunology. The organization utilizes a specialized drug discovery platform that combines chemoproteomics, covalent chemistry, and machine learning to identify novel binding sites on proteins and support protein degradation approaches. Operating with a focus on genetically-defined patient populations, the enterprise launched with $67 million in Series A funding to scale its initial team of 10 employees. The company's financial backers include prominent venture capital firms such as Deerfield Management, MPM Capital, DCVC Bio, and RA Capital Management. The executive team previously established other successful biotech firms, including Blueprint Medicines, which was acquired by Sanofi, and Warp Drive Bio, which was acquired by Revolution Medicines. Frontier Medicines was founded in 2018 by Chris Varma, Daniel Nomura, and Roberto Zoncu.
Key people at Frontier Medicines.
Frontier Medicines has raised $256.0M in total across 4 funding rounds.
Frontier Medicines's investors include Advanced Technology Ventures, Johnson & Johnson Innovation, Novo Ventures, RA Capital, Venrock, RA Capital Management.
Frontier Medicines is a clinical‑stage precision therapeutics company that uses chemoproteomics, covalent chemistry and machine‑learning to find druggable “hotspots” across the proteome and develop small‑molecule medicines for genetically defined patient populations—initially focused on oncology and immunology[5][2].[1]
High‑Level Overview
For a portfolio company summary (Frontier as a product‑building company): Frontier builds a chemoproteomics‑driven drug discovery platform and a pipeline of small‑molecule precision medicines (e.g., programs against KRAS G12C and p53 Y220C) that serve oncology patients with genetically defined tumors and clinical teams seeking differentiated therapies; the company addresses the problem of “undruggable” proteins by mapping binding hotspots and advancing covalent fragments into optimized leads, and it has progressed to clinical‑stage programs (lead FMC‑376 in KRAS G12C in early clinical testing) and strategic partnerships that indicate growth momentum[2][6][3].
Origin Story
Core Differentiators
Role in the Broader Tech/Drug‑Discovery Landscape
Quick Take & Future Outlook
Quick take: Frontier Medicines stands at the intersection of cutting‑edge chemoproteomics and machine‑assisted drug design with an explicit platform‑to‑pipeline strategy; its near‑term fate hinges on clinical readouts and the platform’s ability to generate tailorable, clinic‑ready leads that outperform existing approaches[3][2].
(If you’d like, I can convert this into a one‑page investor brief, a slide outline, or a short competitive mapping against other chemoproteomics/covalent drug discovery firms.)
Frontier Medicines has raised $256.0M across 4 funding rounds. Most recently, it raised $20.0M Series C Extension in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 25, 2024 | $20.0M Series C Extension | ||
| Feb 1, 2024 | $80.0M Series C | Advanced Technology Ventures, Johnson & Johnson Innovation, Novo Ventures, RA Capital, Venrock | |
| Jul 1, 2021 | $89.0M Series B | RA Capital Management | Advanced Technology Ventures, Novo Ventures, Venrock |
| Jun 25, 2019 | $67.0M Series A |